Compare ADMA Biologics Inc (ADMA) vs Wendys Co (WEN) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs Wendys Co — how do they compare? ADMA Biologics Inc trades at $9.28 (market cap $2.13B), while Wendys Co trades at $7.4 (market cap $1.48B). The key difference: ADMA Biologics Inc is the larger of the two by market cap, and Wendys Co pays a 7.2% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | WEN | |
|---|---|---|
Market Cap | $2.13B | $1.48B |
Sector | Health | Consumer Cyclical |
52-Week High | $20.38 | $11.33 |
52-Week Low | $7.60 | $6.17 |
Enterprise Value | $2.20B | $5.30B |
Dividend Yield | — | 7.2% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
Wendy's (WEN) trades at $7.78, down 9.53% today but up significantly from recent lows amid retail-driven momentum. The stock shows strong valuation metrics with P/E of 10.26 and P/S of 0.69, while recent earnings have consistently beaten expectations. Technical indicators suggest a bullish trend with key support at $7 and resistance at $8-9 levels. Recent news highlights digital sales growth and China expansion plans as potential catalysts.
The outlook remains mixed with fundamental challenges including declining net income margins (6.77% in 2025) and negative cash flow trends offset by attractive valuation and dividend yield. Key risks include weak U.S. traffic and cost inflation, while opportunities lie in international expansion and digital initiatives. Analyst consensus leans cautious with 65% hold ratings despite recent momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Wendys Co
The Wendy's Company is the second-largest burger quick-service restaurant, or QSR, chain in the United States by systemwide sales, with $11.1 billion in 2021, narrowly edging Burger King ($10.3 billion) and clocking in well behind wide-moat McDonald's ($45.7 billion). After divestitures of Tim Hortons (2006) and Arby's (2011), the firm manages just the burger banner, generating sales across a footprint that spans almost 7,000 total units in 30 countries. Wendy's generates revenue from the sale of hamburgers, chicken sandwiches, salads, and fries throughout its company-owned footprint, through franchise royalty and marketing fund payments remitted by its franchisees, which account for 94% of stores, and through franchise flipping and advisory fees.
Read more on WEN →
